Hypertrophic cardiomyopathy in children

Asian Cardiovasc Thorac Ann. 2022 Jan;30(1):92-97. doi: 10.1177/02184923211041285. Epub 2021 Sep 27.

Abstract

Hypertrophic cardiomyopathy (HCM) characterized by asymmetric ventricular septal hypertrophy, is the commonest cause of sudden cardiac death (SCD) in the young. The underlying etiology of HCM in the childhood and adolescent patients is diverse. Moreover, the prognosis of pediatric HCM depends on the age of presentation and etiology. Despite the complexity of children with obstructive HCM, surgical treatment results in a favorable outcome for carefully selected patients in experienced tertiary referral center in contemporary era. Implantable cardioverter-defibrillator (ICD) remains the most effective and reliable treatment to prevent SCD. New pediatric SCD risk prediction model, which has good discrimination and calibration and can distinguish patients who are most benefit from an ICD implantation, is expected to be further refined in the future.

Keywords: Hypertrophic cardiomyopathy; children; sudden cardiac death; surgical septal myectomy.

MeSH terms

  • Adolescent
  • Cardiomyopathy, Hypertrophic* / complications
  • Cardiomyopathy, Hypertrophic* / diagnostic imaging
  • Cardiomyopathy, Hypertrophic* / therapy
  • Cardiomyopathy, Hypertrophic, Familial* / complications
  • Child
  • Death, Sudden, Cardiac / etiology
  • Death, Sudden, Cardiac / prevention & control
  • Defibrillators, Implantable* / adverse effects
  • Humans
  • Risk Assessment
  • Risk Factors
  • Treatment Outcome